1887

Abstract

The inhibitory effect of diallyl sulphide (DAS) and diallyl disulphide (DADS) against meticillin-resistant (MRSA) infection in diabetic mice was studied. The influence of these agents on the plasma levels of fibronectin, C-reactive protein (CRP), fibrinogen, interleukin (IL)-6 and tumour necrosis factor- (TNF-), and on the activity of plasminogen activator inhibitor-1 (PAI-1), antithrombin III (AT-III) and protein C, in MRSA-infected diabetic mice was examined. To induce diabetes, mice were treated intraperitoneally with streptozotocin for 5 consecutive days. Ten clinical MRSA isolates obtained from infected patients were used in this study. Diabetic mice were infected by injecting 200 μl MRSA/PBS suspension containing 10 c.f.u. via the tail vein. At day 4 post-infection, 200 μl DAS or DADS was administrated twice orally with an interval of 12 h. Eight hours after each administration, the blood and organs of mice were collected. Results showed that DAS and DADS significantly decreased MRSA viability in the kidney ( <0.05), with administration of each agent twice showing a greater inhibitory effect than when given once ( <0.05). MRSA infection in diabetic mice significantly elevated the plasma levels of IL-6 and TNF- ( <0.05). DAS or DADS given once did not affect the plasma levels of IL-6 and TNF- ( >0.05); however, DAS or DADS given twice significantly decreased the plasma levels of both IL-6 and TNF- ( <0.05). DAS and DADS treatments also significantly reduced the plasma levels of CRP, fibronectin and fibrinogen ( <0.05). DAS or DADS treatment did not affect PAI-1 activity ( >0.05), but DAS or DADS given twice significantly increased AT-III activity ( <0.05). DADS given twice elevated protein C activity ( <0.05). MRSA infection significantly increased malondialdehyde levels in the kidney and spleen ( <0.05), and these levels were significantly decreased by treatment with DAS or DADS ( <0.05). These data suggest that DAS and DADS could provide multiple protective functions against MRSA infection in diabetic mice.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46998-0
2007-06-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/6/803.html?itemId=/content/journal/jmm/10.1099/jmm.0.46998-0&mimeType=html&fmt=ahah

References

  1. Asakawa H., Tokunaga K., Kawakami F. 2000; Elevation of fibrinogen and thrombin–antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 14:121–126 [CrossRef]
    [Google Scholar]
  2. Chang S. C., Hsieh W. C., Liu C. 2000; High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan. Diagn Microbiol Infect Dis 36:107–112 [CrossRef]
    [Google Scholar]
  3. Cossart P. 1997; Host/pathogen interactions: subversion of the mammalian cell cytoskeleton by invasive bacteria. J Clin Invest 99:2307–2311 [CrossRef]
    [Google Scholar]
  4. Hanaki H., Akagi H., Masaru Y., Otani T., Hyodo A., Hiramatsu K. 1995; TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 39:1120–1126 [CrossRef]
    [Google Scholar]
  5. Hiramatsu K., Hanaki H., Ino T. 1997; Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135–136 [CrossRef]
    [Google Scholar]
  6. Jain S. K., Palmer M. 1997; The effect of oxygen radical metabolites and vitamin E on glycosylation of proteins. Free Radic Biol Med 22:593–596 [CrossRef]
    [Google Scholar]
  7. Jang T. N., Kuo B. I., Shen S. H. 1999; Nosocomial Gram-negative bacteria in critically ill patients: epidemiologic characteristics and prognostic factors in 147 episodes. J Formos Med Assoc 98:465–473
    [Google Scholar]
  8. Lowy F. D. 1998; Staphylococcus aureus infections. N Engl J Med 339:520–532 [CrossRef]
    [Google Scholar]
  9. McCarty M. F. 1999; Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 52:465–477 [CrossRef]
    [Google Scholar]
  10. Mohamed-Ali V., Armstrong L., Vlark D., Bolton C. H., Pinkney J. H. 2001; Evidence for the regulation of levels of plasma adhesion molecules by inflammatory cytokines and their soluble receptors in type 1 diabetes. J Intern Med 250:415–421 [CrossRef]
    [Google Scholar]
  11. Muller A., Schott-Ohly P., Dohle C. 2002; Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology 205:35–50 [CrossRef]
    [Google Scholar]
  12. NCCLS 1999 Performance Standards for Antimicrobial Susceptibility Testing , 9th informational supplement. Approved standard M100-S9 Villanova, PA: National Committee for Clinical Laboratory Standards;
    [Google Scholar]
  13. Sakata N., Meng J., Takebayashi S. 2000; Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 7:169–176 [CrossRef]
    [Google Scholar]
  14. SAS 1990 SAS User’s Guide: Statistics Cary, NC: SAS Institute;
    [Google Scholar]
  15. Shimada A., Charlton B., Rohane P., Taylor-Edwards C., Fathman C. G. 1996; Immune regulation in type 1 diabetes. J Autoimmun 9:263–269 [CrossRef]
    [Google Scholar]
  16. Tomita M., Dragoman M., Worcester H., Conran P., Santoro T. J. 2004; Proinflammatory cytokine genes are constitutively overexpressed in the heart in experimental systemic lupus erythematosus: a brief communication. Exp Biol Med (Maywood 229:971–976
    [Google Scholar]
  17. Tsao S. M., Hsu C. C., Yin M. C. 2003; Garlic extract and two diallyl sulphides inhibit methicillin-resistant Staphylococcus aureus infection in BALB/cA mice. J Antimicrob Chemother 52:974–980 [CrossRef]
    [Google Scholar]
  18. Tsao S. M., Hsu C. C., Yin M. C. 2006; Meticillin-resistant Staphylococcus aureus infection in diabetic mice enhanced inflammation and coagulation. J Med Microbiol 55:379–385 [CrossRef]
    [Google Scholar]
  19. Wu C. C., Sheen L. Y., Chen H. W., Tsai S. J., Lii C. K. 2001; Effects of organosulfur compounds from garlic oil on the antioxidation system in rat liver and red blood cells. Food Chem Toxicol 39:563–569 [CrossRef]
    [Google Scholar]
  20. Yin M. C., Hwang S. W., Chan K. C. 2002; Nonenzymatic antioxidant activity of four organosulfur compounds derived from garlic. J Agric Food Chem 50:6143–6147 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46998-0
Loading
/content/journal/jmm/10.1099/jmm.0.46998-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error